Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3349238 | 0.81 | BRD4 (0.46) | BRD4SOS1 | |
| SCHEMBL3347941 | 0.79 | PIK3CD (0.40) | BRD4SOS1CREBBPATAD2 | |
| SCHEMBL15552065 | 0.78 | BRD4 (0.40) | BRD4SOS1CREBBPTLR4TLR9 | |
| SCHEMBL15551039 | 0.76 | BRD4 (0.66) | BRD4ADORA2AADORA1ADORA2BCREBBP | |
| SCHEMBL31207403 | 0.75 | BRD4 (0.44) | BRD4SOS1ADORA2AADORA1ADORA2B | |
| SCHEMBL23166181 | 0.75 | BRD4 (0.49) | BRD4ADORA2AADORA1ADORA2BCREBBP | |
| SCHEMBL29710178 | 0.75 | BRD4 (0.49) | BRD4ADORA2AADORA1ADORA2BCREBBP | |
| SCHEMBL6523541 | 0.73 | BRD4 (0.43) | BRD4SOS1ADORA2AADORA1ADORA2B | |
| SCHEMBL1912411 | 0.72 | NSD2 (0.46) | BRD4SOS1ADORA2AADORA1ADORA2B | |
| SCHEMBL15552985 | 0.72 | BRD4 (0.62) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435990-B2 | Dihydropyrimidone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-02-03 | — | — | US | disclosed |
| US-20100160384-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160384-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX6, P2RX3 | BRD4 1409/4885SOS1 4609/4885ADORA2A 21/4885 |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX7, P2RX3 | BRD4 1198/4885SOS1 3975/4885ADORA2A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.